Physician profile
Deep Buch
NPI 1518113786
$6,645.87
in general payments reported to CMS, 2019-2025
20 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $362 · 2021: $745 · 2022: $996 · 2023: $968 · 2024: $1,236 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,399.14 |
| Education | $211.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,345.13 | 2019-2022 | |
| Abbvie INC. | $807.65 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $670.92 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $665.91 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $590.47 | 2019-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $490.25 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $461.39 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $459.01 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $278.65 | 2024-2025 | Cobenfy |
| Corium, LLC | $236.03 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $233.80 | 2024-2025 | Auvelity |
| Alkermes, INC. | $107.23 | 2019-2025 | Aristada, Lybalvi |
| Indivior INC. | $72.42 | 2022-2025 | Sublocade |
| Allergan, INC. | $64.99 | 2020 | |
| Jazz Pharmaceuticals INC. | $53.71 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $32.56 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $29.28 | 2024 | Qelbree |
| Idorsia Pharmaceuticals US INC | $19.45 | 2024 | Quviviq |
| Noven Therapeutics, LLC | $15.42 | 2024 | Xelstrym |
| Shire North American Group INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Buch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.